

If you are in any doubt as regards the contents of this email, you are recommended to seek your own financial advice immediately from your stockbroker, bank manager, solicitor or other independent adviser: (i) authorised under the Financial Services and Markets Act 2000 if you are in the United Kingdom; (ii) duly authorised under the South African Financial Advisory and Intermediary Services Act 37 of 2002 (as amended), if you are in South Africa; or (iii) from another appropriately authorised independent financial adviser if you are in a territory outside the United Kingdom or South Africa. If you have sold or otherwise transferred all of your ordinary shares in Mediclinic International plc, please send this email at once to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. If you have sold or transferred only part of your holding of ordinary shares in Mediclinic International plc, you should retain this email and consult the bank, stockbroker or other agent through whom the sale was effected. However, this email should not be forwarded or transmitted, in whole or in part, into any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.

The release, publication or distribution of this email and any accompanying documents (in whole or in part) in or into or from jurisdictions other than the United Kingdom, South Africa or Namibia may be restricted by the laws of those jurisdictions and therefore persons into whose possession this email comes should inform themselves about, and observe, any such restrictions. Failure to comply with any such restrictions may constitute a violation of the securities laws of any such jurisdiction. Further details in relation to overseas shareholders of Mediclinic International plc are set out in the Scheme Document (as defined below).

To: Mediclinic International plc ("**Mediclinic**") shareholders

Notification of publication of important documentation in relation to the recommended cash acquisition of Mediclinic by Manta Bidco Limited ("Bidco**") (a newly formed company owned by joint offerors: (i) Remgro Limited ("**Remgro**") (through the Relevant Remgro Subsidiaries); and (ii) SAS Shipping Agencies Services S.à r.l. ("**SAS**"), a wholly owned subsidiary of MSC Mediterranean Shipping Company SA).**

On 4 August 2022, the boards of directors of Mediclinic (excluding the Remgro representative), Remgro and SAS announced that they had agreed the terms of a recommended cash offer pursuant to which Bidco proposes to acquire the entire issued and to be issued share capital of Mediclinic (the "**Acquisition**"), other than the 328,497,888 Mediclinic Shares already owned by the Relevant Remgro Subsidiaries. The Acquisition is intended to be effected by means of a Court-sanctioned scheme of arrangement (the "**Scheme**") under Part 26 of the Companies Act. The next step in the process is for Mediclinic Shareholders and Scheme Shareholders to vote on the Acquisition.

Please accept this email as notification that a scheme document published today, which contains further details of the Acquisition, the Scheme, an explanatory statement in compliance with section 897 of the Companies Act and notices of the shareholder meetings (the "**Scheme Document**"), is now available to view at, and can be downloaded from, Mediclinic's website at <https://investor.mediclinic.com/regulatory-news/offer-mediclinic-international-plc>. For the avoidance of doubt, the content of Mediclinic's website is not incorporated into, and does not form part of, this email.

Please read the Scheme Document carefully. Please note that this email is not a summary of the information and proposals set out in the Scheme Document and should not be regarded as a substitute for reading the Scheme Document in full. You should read the Scheme Document in full before making a decision. Any capitalised terms not otherwise defined in this email shall have the meaning given to them in the Scheme Document.

What do you need to do?

In order to become effective, the Scheme requires approval of shareholders at two meetings – the Court Meeting and the General Meeting – both of which will be held at The Auditorium, UBS Investment Bank, 5 Broadgate, London, EC2M 2QS on 26 September 2022. The Court Meeting

will start at 12:00 p.m. (London time) and the General Meeting at 12:15 p.m. (London time) (or as soon thereafter as the Court Meeting has concluded or been adjourned).

It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair representation of opinion of Scheme Shareholders. Whether or not you intend to attend and/or vote at the Meetings, you are therefore strongly advised to submit proxy appointments and voting instructions for the Court Meeting and the General Meeting as soon as possible, using any of the methods set out in the Scheme Document.

You are entitled to appoint a proxy or proxies to attend, to ask questions and, on a poll, to vote instead of you. Mediclinic Shareholders will receive hard copy Forms of Proxy for the Court Meeting and the General Meeting. We note that your preference is to receive electronic communications from Mediclinic, but the City Code on Takeovers and Mergers (the “Code”) requires that we send Mediclinic Shareholders hard copies of these documents. Accordingly, we are sending Mediclinic Shareholders both this email in accordance with your preferences and a hard copy letter enclosing the Forms of Proxy.

You can submit your proxy appointment by post, online through the website of the Company’s UK Registrar, Computershare, at www.investorcentre.co.uk/eproxy (see below your Control Number(s), Shareholder Reference Number and PIN for accessing the voting website) or, if applicable, by using the CREST electronic proxy appointment service. Please refer to the Scheme Document for detailed information about how to appoint proxies.

Court Meeting Control Number: 918064
General Meeting Control Number: 918065
SRN: [[SRN]]
PIN: [[PIN]]

Proxy appointments should be registered so as to be received as soon as possible and in any event not later than 12:00 p.m. (London time) on 22 September 2022 (for the Court Meeting) and 12:15 p.m. (London time) on 22 September 2022 (for the General Meeting), or, if in either case the Meeting is adjourned, the relevant Form of Proxy should be received not later than 48 hours (excluding any part of such 48 hours period falling on a non-UK Business Day) before the time fixed for the adjourned Meeting.

Proxy appointments for the General Meeting will not be valid if not lodged by this time. If a proxy appointment is not made for the Court Meeting by the relevant time, the BLUE Form of Proxy you receive may be scanned and emailed to #ukcscmscrestmessages@computershare.co.uk or presented in person to the Computershare representative who will be present at the Court Meeting, any time prior to the commencement of the Court Meeting.

The appointment of a proxy will not prevent you from attending and voting at the Court Meeting or the General Meeting, or any adjournments thereof, in person should you wish to do so and should you be so entitled.

Questions you may have

If you have any questions about the Scheme Document, the Court Meeting or the General Meeting or other queries in relation to your shareholding, or are in any doubt as to how to complete the Forms of Proxy or to submit your proxies electronically, please call Computershare between 8.30 a.m. and 5.30 p.m. Monday to Friday (excluding public holidays in England and Wales) on 0370 703 6022 from the UK or +44 370 703 6022 from overseas. Calls from outside the UK will be charged at the applicable international rate. Different charges may apply to calls from mobile telephones. Please note that calls may be monitored or recorded, and Computershare cannot provide advice on the merits of the Acquisition or the Scheme or give any financial, legal or tax advice.

Right to request hard copies

You may request a hard copy of the Scheme Document or any information incorporated into the Scheme Document by reference to another source, free of charge, by (i) calling Computershare using the helpline details set out above or (ii) writing to Computershare at The Pavilions, Bridgwater Road, Bristol, BS99 6ZY stating your name, and the address to which the hard copy should be sent.

Persons with information rights

If you are an indirect investor through a nominee shareholder, we have received notification from a nominee shareholder that, as an underlying investor in Mediclinic, you have elected to receive "information rights" in accordance with the Companies Act. This entitles you to receive copies of documents sent to shareholders on our share register. This email therefore notifies you that a scheme document is available on our website at <https://investor.mediclinic.com/regulatory-news/offer-mediclinic-international-plc>. Your main contact in terms of your investment remains the registered shareholder, custodian or broker who administers your investment. Any changes or queries relating to your personal details or shareholding must be directed to your existing contact.

Thank you for taking the time to read through this email and the Scheme Document, and thank you in advance for voting at the Meetings.

Yours faithfully,

A handwritten signature in black ink, appearing to read 'Inga Beale', written in a cursive style.

Dame Inga Beale
Chair
Mediclinic International plc

The directors of Mediclinic accept responsibility for the information contained in this email relating to Mediclinic. To the best of the knowledge and belief of the directors of Mediclinic (who have taken all reasonable care to ensure that such is the case) the information contained in this email is in accordance with the facts and does not omit anything likely to affect the import of such information.

Addresses may be provided to Bidco

Please be aware that addresses, electronic addresses and certain other information provided by you for the receipt of communications from Mediclinic may be provided to Bidco during the offer period as required under Section 4 of Appendix 4 of the City Code on Takeovers and Mergers (the "Code").

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 p.m. (London time) on the tenth business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129.